



BUG

British Uro-oncology Group

Annual Meeting Brighton Metropole

25 - 26 September 2026

PROGRAMME

FRIDAY 25 September

10.00	Registration, refreshments, exhibition and poster viewing
11.00	Welcome & Uro-oncology Round Up Chair: <i>Amit Bahl, Chair, BUG</i>
11.05	Prostate <i>Joe O'Sullivan, Academic Clinical Oncologist, Queen's University Belfast</i>
11.25	Bladder <i>Alison Birtle, Consultant Clinical Oncologist, Royal Preston Hospital</i>
11.45	Renal <i>Lisa Pickering, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust</i>
12.00	Testicular <i>Robert Huddart, Professor and Honorary Consultant in Urological Oncology, Institute of Cancer Research</i>
12.10	Penile <i>Amit Bahl, Consultant Clinical Oncologist, University Hospitals Bristol</i>
12.20	Discussion
12.30	Lunch, exhibition and poster viewing
13.45-14.30	Main session – Prostate Chair: <i>Joe O'Sullivan, Academic Clinical Oncologist, Queen's University Belfast</i> - PSMA radioligand <i>Amarnath Challapalli, Consultant Clinical Oncologist, Bristol Cancer Institute</i> - PARPs <i>Rob Jones, Professor and Honorary Consultant, University of Glasgow & The Beatson West of Scotland Cancer Centre</i> - Results of the toxicity of the PIVOTALboost trial <i>Isabel Syndikus, Consultant Clinical Oncologist, The Clatterbridge Cancer Centre NHS Foundation Trust</i>
14.30-15.30	Seminar sessions 1
1A	Bladder Chair: <i>Vishwanath Hanchale, Chair BAUS Section of Oncology, Liverpool University Hospitals NHS Foundation Trust</i> <i>Helena Burden, Consultant Urological Surgeon, North Bristol NHS Trust</i> <i>Gokul Kandaswamy, Consultant Urological Surgeon, Swansea</i> Case based discussions: Session 1: NMIBC - High-risk NMIBC – BCG or early cystectomy? - BCG-unresponsive NMIBC – When is it time to change strategy? Session 2: Rare histological subtypes - Micropapillary bladder cancer – Is early radical treatment justified? - Small cell carcinoma of the bladder – A different disease, a different pathway Session 3: Recently approved NICE-appraised therapies - Peri-operative immunotherapy in MIBC – Selecting patients for Durvalumab-based treatment - Advanced urothelial cancer – Integrating Enfortumab Vedotin, Pembrolizumab and Erdafitinib into clinical practice



BUG

British Uro-oncology Group

Annual Meeting Brighton Metropole

25 - 26 September 2026

1B	Prostate Chair: <i>Prantik Das, Consultant Clinical Oncologist, University Hospitals of Derby and Burton NHS Foundation Trust</i> Practice enhancing – practical aspect of clinical practice, complex cases SABR Reirradiation • <i>Suneil Jain, Consultant Clinical Oncologist, Queen's University, Belfast</i> • <i>Ann Henry, Professor in Clinical Oncology, Leeds Teaching Hospitals NHS Trust</i>
1C	Renal Chair: <i>Balaji Venugopal, Consultant in Medical Oncology, The Beatson West of Scotland Cancer Centre, Glasgow</i> • <i>Natalie Charnley, Consultant Clinical Oncologist, Lancashire Teaching Hospitals NHS Foundation Trust</i> • <i>Anand Sharma, Consultant Medical Oncologist, Mount Vernon Cancer Centre</i> Case based discussion
15.30	Refreshments, exhibition and poster viewing
16.15-17.00	Main session - Optimal systemic treatment of locally advanced bladder cancer Chair: <i>Yee Pei Song, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester</i> • Neo-adjuvant and adjuvant systemic treatments <i>Sally Appleyard, Consultant Clinical Oncologist, University Hospitals Sussex</i> • The practical role of ctDNA <i>Andrew Hudson, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester</i> • Definitive treatment for localised muscle invasive bladder cancer <i>Mohini Varughese, Consultant Clinical Oncologist, Royal Devon University Hospitals NHS Foundation Trust</i>
17.00-17.30	Why should you look at my poster? Chair: <i>Mark Beresford, Consultant Clinical Oncologist, Royal United Hospital, Bath</i> One minute presentations from each poster author
17.30-18.15	Welcome reception, exhibition and poster viewing
19.30	Predinner drinks
20.00	Conference dinner



BUG

British Uro-oncology Group

Annual Meeting Brighton Metropole

25 - 26 September 2026

SATURDAY 26 September

08.15	Registration, refreshments, exhibition and poster viewing
08.45-09.15	BUG Annual General Meeting (<i>members only</i>)
09.15-10.00	Main session – Systemic management of localised renal cancer Chair: <i>Rhona McMenemin, Consultant Clinical Oncologist, Aberdeen Royal Infirmary</i> • Neoadjuvant/adjuvant data <i>Giuseppe Banna, Consultant Medical Oncologist, Portsmouth Hospitals University NHS Trust</i> • Non clear cell <i>Sarah Rudman, Consultant Medical Oncologist, Guy's and St Thomas' NHS Foundation Trust</i> • SABR <i>Vincent Khoo, Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust</i>
10.00-11.00	Seminar sessions 2
2A	Prostate – Survivorship in prostate cancer Chair: <i>Hilary Glen, Consultant Medical Oncologist, The Beatson West of Scotland Cancer Centre, Glasgow</i> • Managing/optimising cardiovascular health for men on ADT <i>Tharshini Ramalingam, Cardio-oncologist, The Royal Brompton Hospital, London</i> • Bone health <i>Carolina Navarro Rodriguez, Clinical Oncology SpR, The Newcastle Upon Tyne Hospitals NHS Foundation Trust</i>
2B	Medico-legal Chair: <i>Rob Jones, Professor and Honorary Consultant, University of Glasgow & The Beatson West of Scotland Cancer Centre</i> • <i>Jeremy Roussak, Barrister (Retired), formerly Kings Chambers, Manchester</i> • <i>Joe O'Sullivan, Academic Clinical Oncologist, Queen's University Belfast</i>
Sat 26 th Sept 10.00-11.00	AI: Role of AI in Urological Cancers Chairs: <i>Alexander Vickers, Clinical SpR, Honorary Research Fellow & BUG Clinical Oncology Trainee Representative, The Christie NHS Foundation Trust & The University of Manchester & Shybi Mohamedkhan, ST4 Medical Oncology SpR and BUG Medical Oncology Trainee Representative, Royal Surrey County Hospital</i> • AI in Uro-oncology Pathology <i>Dr Jon Griffin, Senior Clinical Lecturer & Consultant Histopathologist, The University of Sheffield</i> • AI and Biobanking in Uro-oncology <i>Abhishek Mahajan, Consultant Radiologist, The Clatterbridge Cancer Centre NHS Foundation Trust</i> • PROSECCA project <i>Dr Archie MacNair, Clinical Oncologist, Edinburgh Cancer Centre</i>
11.00	Refreshments, exhibition and poster viewing



BUG

British Uro-oncology Group

Annual Meeting Brighton Metropole

25 - 26 September 2026

11.45-12.30	Helen Patterson Award for Registrar Research
11.45	Chair's welcome
11.50	2026 Winner's presentation <i>Alexander Vickers, Clinical SpR & Honorary Research Fellow, The Christie NHS Foundation Trust & The University of Manchester</i>
11.55	Registrar presentations introduction
12.00	Second-line Tivozanib after Combination Nivolumab plus Ipilimumab in Patients with Metastatic Renal Cell Carcinoma <i>Fergal Doherty, Junior Clinical Fellow, The Christie NHS Foundation Trust</i>
12.10	Implementation and evaluation of PET/CT-informed prostate bed contouring within POINTER-PC and PACE Post-op trials <i>Carina Guo, Research Clinical Fellow, RTTQA</i>
12.20	CD8 infiltration and FOXP3/CD8 immune balance define PD-L1-associated phenotypes and survival outcomes in muscle-invasive bladder cancer <i>Marija Miletic, Senior Clinical Fellow in Translational Research, The Christie NHS Foundation Trust</i>
12.30-13.15	Main session: Chair: <i>Amit Bahl, Chair, BUG</i> - NPCA Noel Clarke, <i>Professor of Urological Oncology, The Christie NHS Foundation Trust</i> - NKCA updates <i>Jan van der Meulen, Professor of Clinical Epidemiology, London School of Hygiene and Tropical Medicine</i> - NHS cancer plan and relevance <i>Stephen Harden, President, The Royal College of Radiologists</i>
13.15-13.30	Closing session: Amit Bahl, Chair, BUG Prize giving Helen Patterson Award for registrar research Best poster prize
13.30-14.30	Lunch and depart

BUG would like to thank the following organisations for their support of the 2026 Annual Meeting

KEY SPONSORS



SUPPORTING SPONSORS



BUG recognises the ABPI Code of Practice and the implications for pharmaceutical companies that support the Annual meeting by way of sponsoring and exhibiting. Industry partners have no input into the educational content of the programme